Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Sarcoma 1Head & Neck 1Gynecologic 1Genitourinary 1Gastrointestinal 1Dermatologic 1

Conditions

Glioblastoma 12Prostatic Neoplasms 11Lung Neoplasms 11Oropharyngeal Neoplasms 10Carcinoma, Non-Small-Cell Lung 10Breast Neoplasms 9Glioma 8Urinary Bladder Neoplasms 7Squamous Cell Carcinoma of Head and Neck 6Neoplasm Metastasis 6Esophageal Neoplasms 6Mouth Neoplasms 5Carcinoma 5Burkitt Lymphoma 5Astrocytoma 5Sarcoma 4Pancreatic Neoplasms 4Laryngeal Neoplasms 4Gliosarcoma 4Carcinoma, Hepatocellular 4Brain Neoplasms 4Adenocarcinoma of Lung 4Adenocarcinoma Of Esophagus 4Uterine Cervical Neoplasms 3Triple Negative Breast Neoplasms 3Stomach Neoplasms 3Rhabdomyosarcoma, Embryonal 3Rhabdomyosarcoma 3Rectal Neoplasms 3Neoplasms 3

Interventions

Oxaliplatin 9Capecitabine 9Paclitaxel 7Fluorouracil 7pembrolizumab 6Leucovorin 6Cisplatin 5zolbetuximab 4Docetaxel 4trastuzumab deruxtecan 3enzalutamide 3durvalumab 3cemiplimab 3Trastuzumab 3Nivolumab 3Irinotecan 3Gemcitabine 3Albumin-Bound Paclitaxel 3fludarabine 2darolutamide 2atezolizumab 2Taxes 2Ramucirumab 2Radiotherapy, Image-Guided 2Radiosurgery 2Pemetrexed 2Cyclophosphamide 2Carboplatin 2130-nm albumin-bound paclitaxel 2vistusertib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Adenocarcinoma × Radiation × 90 days × Clear all
NCT03132922 2026-06-04

MAGE-A4ᶜ¹º³²T for Multi-Tumor

USWM, LLC (dba US WorldMeds)

Phase 1 Active not recruiting
71 enrolled 20 charts
DermatologicGastrointestinalGenitourinaryGynecologicHead & NeckSarcomaThoracic

Adenocarcinoma, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms, Head and Neck Neoplasms, Melanoma, Neoplasm Metastasis, Ovarian Neoplasms, Sarcoma, Stomach Neoplasms, Sarcoma, Synovial, Liposarcoma, Myxoid

Data powered by HemOnc (CC BY 4.0) Colophon âš¡